Drugs / Thrombomodulin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06381661 | May 2026 → Jun 2028 expected | infectious disease with sepsis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thrombomodulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06381661 ↗ |
| Known as | rhTM | “Recombinant human thrombomodulin (rhTM) 0.06 mg/kg/j IV, for 7 days” NCT06381661 ↗ |
| Route | Intravenous | “0.06 mg/kg/j IV” NCT06381661 ↗ |